AUTHORS
Dany Nassar, MD, Paul Koller, MD2, Somedeb Ball, MD3, Courtney DiNardo, MD, MSCE4, Naval Daver, MD5, Tapan Kadia I, MD6, Musa Yilmaz, MD7, Nicholas Short, MD8, Ghayas C. Issa, MD9, Ian Bouligny, M.D.10, Alexandre Bazinet, MD, MSc11, Eitan Kugler, MD PhD12, Wei Ying Jen, BM BCh, FRCPath13, Muharrem Muftuoglu, MD14, Ruitao Lin, PhD15, Miran Moon16, Soo-Yeon Jang17, Guillermo Garcia-Manero, MD18, Farhad Ravandi, MD19, Abhishek Maiti, MBBS20, Guru Subramanian Guru Murthy, MD21
AFFILIATIONS
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 City of Hope National Medical Center, Duarte, California, United States
3 Vanderbilt University Medical Center, Nashville, Tennessee, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
11 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
12 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
13 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
14 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
15 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
16 PeLeMed Co., Ltd., Seoul, Korea, Rep. of South
17 PeLeMed Co., Ltd., Seoul, Korea, Rep. of South
18 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
19 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
20 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
21 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
ABSTRACT
Background
FLT3 mutations are detected in nearly 30% of newly diagnosed acute myeloid leukemia (AML). While FLT3 inhibitors have significantly improved outcomes, 10 to 30% patients may be refractory and 20 to 30% patients may relapse, leading to suboptimal long-term outcomes. Baseline RAS pathway mutations confer inferior outcome in these patients. Patients with relapsed/refractory (R/R) FLT3-mutated disease have dismal outcomes with median overall survival of 6 months. Furthermore, FLT3 is frequently overexpressed in FLT3 wild-type AML and derive benefit from FLT3 inhibition, providing a rationale for targeting FLT3 beyond patients with FLT3-mutated AML. Consequently, novel agents are needed to improve outcomes in such patients.
PLM-102 is an oral, third generation, highly potent, type I FLT3 inhibitor with activity against FLT3 wild-type and mutant receptors, including F691L. In preclinical studies, PLM-102 showed approximately 18- to 25-fold greater antiproliferative activity than gilteritinib in FLT3-ITD–mutated AML cell lines. It inhibited FLT3 phosphorylation and downstream STAT3, STAT5, AKT, MEK, and ERK signaling, leading to cell-cycle arrest and apoptosis. PLM-102 also demonstrated robust antileukemic activity in cell line and patient-derived xenograft models, including resistant models driven by NRAS/PTPN11 as well as the gatekeeper mutation FLT3 F691L. Based on this, we initiated a phase I study to evaluate the safety, tolerability, and preliminary clinical activity of PLM-102 in patients with R/R AML.
Methods
This is an investigator-initiated, first-in-human, multicenter, phase I dose-escalation study to evaluate PLM-102 monotherapy in adults with R/R AML or MDS/AML. Eligible patients must have an Eastern Cooperative Oncology Group performance status of 0–2 and have progressed after, been intolerant of, declined, or been ineligible for available standard therapies. Patients with actionable mutations and approved targeted treatment options are eligible only after those therapies have been exhausted or are considered unsuitable (NCT07549464).
PLM-102 will be administered orally once daily in continuous 28-day cycles. Six planned dose levels (50, 100, 150, 225, 300, and 400 mg daily) will be evaluated using a Bayesian optimal interval (BOIN) design, with enrollment of up to 36 patients during dose escalation. Up to two dose levels demonstrating preliminary antileukemic activity may be expanded by enrolling up to nine additional patients each, for a maximum study population of 54 patients. Treatment will continue until disease progression, unacceptable toxicity, allogeneic stem-cell transplantation, withdrawal of consent, or another protocol-defined discontinuation criterion.
The primary objectives are to characterize the safety and tolerability of PLM-102, assess dose-limiting toxicities, and determine the recommended phase II dose based on the overall safety, pharmacokinetic, pharmacodynamic, and preliminary efficacy profile. Secondary endpoints include complete remission (CR/CRh) rate, overall response rate (CR, CRh, CRi, MLFS, or PR) within four treatment cycles, duration of response, and overall survival. Exploratory analyses will evaluate PLM-102 metabolites, pharmacodynamic target inhibition using the plasma inhibitory activity assay, and single-cell proteomic profiling to investigate mechanisms of response and resistance. This study is designed to define the safety profile, biologically active dose range, and early clinical activity of PLM-102 across molecular subgroups of R/R AML.
Funding support: NCI MDA CCSG, PeLeMed Inc.
DISCLOSURES
Dany Nassar, MD: No relevant conflicts of interest to declare.